^
Association details:
| Biomarker: | KRAS G12D |
|---|---|
| Cancer: | Ovarian Serous Adenocarcinoma |
| Drug: | avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor) + defactinib (VS-6063) (FAK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract CT143: Phase I study of the combination of a RAF-MEK inhibitor CH5126766 and FAK inhibitor defactinib in an intermittent dosing schedule with expansions in KRAS mutant cancers
Published date:
04/27/2020
Excerpt:
The response rate was 67% (4/6) or 50% (4/8) in KRASM LGSOC or all LGSOC patients treated to date, respectively. A range of KRASM were found in tumors of LGSOC patients who responded (G12V, G12A and G12D). Of the 4 patients with LGSOC who have responded to treatment, 3 have had a prior MEK inhibitor and are currently are on study for a median of 20.5 months (range 7-23 months).
DOI:
10.1158/1538-7445.AM2020-CT143
Trial ID:
